Sequential FDG-PET/CT as a Biomarker of Response to Renal Cancer

Citation Report

#	Article	IF	Citations
1	Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging, 2011, 11, 259-265.	1.2	37
2	Successful one stage operation for a synchronous, duodenal carcinoma, colonic carcinoma and renal oncocytoma in an adult patient. World Journal of Surgical Oncology, 2011, 9, 99.	0.8	1
3	Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2011, 17, 5841-5843.	3.2	8
4	Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology, 2012, 4, 253-265.	0.9	30
5	Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics: Targets and Therapy, 2012, 6, 395.	3.0	14
6	Primary renal cell carcinoma. Nuclear Medicine Communications, 2012, 33, 967-973.	0.5	24
8	Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis, 2012, 15, 623-641.	3.7	74
9	Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. British Journal of Cancer, 2012, 107, 1009-1016.	2.9	31
10	Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer, 2012, 12, 162.	1.1	68
11	Positron Emission Tomography in Renal Cell Carcinoma: An Imaging Biomarker in Development. Seminars in Nuclear Medicine, 2012, 42, 221-230.	2.5	31
12	Difficulty in predicting survival in metastatic renal cancer. Lancet Oncology, The, 2012, 13, 859-860.	5.1	9
13	Renal Cancer. , 2012, , 61-75.		0
14	Management of Advanced Genitourinary Tumors. Tumori, 2012, 98, 264-266.	0.6	2
15	Second-Line Therapy After VEGF Targeted Therapy in Metastatic Renal Cancer: A Law of Diminishing Returns. Clinical Genitourinary Cancer, 2012, 10, 67-68.	0.9	7
16	Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. European Urology, 2012, 61, 307-316.	0.9	52
18	Predictive Markers in Advanced Renal Cell Carcinoma. Seminars in Oncology, 2013, 40, 459-464.	0.8	13
19	The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer. Clinical Cancer Research, 2013, 19, 6924-6934.	3.2	62
20	Optimal Management of Metastatic Renal Cell Carcinoma: Current Status. Drugs, 2013, 73, 427-438.	4.9	95

#	ARTICLE	IF	CITATIONS
21	A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. Annals of Oncology, 2013, 24, 2098-2103.	0.6	41
22	<scp>FDG</scp>â€‹<scp>PET</scp> as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Medicine, 2013, 2, 545-552.	1.3	54
23	Imagen Thecniques in Renal-Cell Carcinoma. , 2013, , .		0
24	Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma. British Journal of Cancer, 2014, 110, 616-624.	2.9	31
25	Predictive biomarkers in renal cell cancer: Insights in drug resistance mechanisms. Drug Resistance Updates, 2014, 17, 77-88.	6.5	56
26	Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT. Clinical Nuclear Medicine, 2014, 39, e320-e324.	0.7	32
27	Assessing the Response to Targeted Therapies in Renal Cell Carcinoma: Technical Insights and Practical Considerations. European Urology, 2014, 65, 766-777.	0.9	32
29	The role of functional imaging in the era of targeted therapy of renal cell carcinoma. World Journal of Urology, 2014, 32, 47-58.	1.2	18
30	Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. Targeted Oncology, 2014, 9, 9-24.	1.7	5
31	Imaging in Clinical Oncology. , 2014, , .		2
32	Precision medicine for metastatic renal cell carcinoma11Disclosures: Guru Sonpavde, MD: Research support from Novartis, Pfizer, and speaker or advisory board for Novartis, Pfizer, and GSK. Toni K. Choueiri, MD: Research support from Pfizer. Advisory board: Pfizer, Novartis, Aveo, GSK, Bayer/Onyx, and Genentech. No speakers bureau.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 5-15.	0.8	16
33	The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ. BMC Cancer, 2014, 14, 390.	1.1	26
34	Volumetric FDG-PET predicts overall and progression- free survival after 14Âdays of targeted therapy in metastatic renal cell carcinoma. BMC Cancer, 2014, 14, 408.	1.1	29
35	A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. European Journal of Cancer, 2014, 50, 2057-2064.	1.3	15
36	The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. Radiology and Oncology, 2014, 48, 219-227.	0.6	39
37	FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging, 2015, 15, 15.	1.2	35
38	Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer. BMC Cancer, 2015, 15, 1097.	1.1	30
39	Molecularly Targeted Staging Strategies in Renal Cell Carcinoma. , 2015, , 541-553.		0

#	ARTICLE	IF	CITATIONS
40	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. Therapeutic Advances in Urology, 2015, 7, 59-68.	0.9	2
42	False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 23.e15-23.e21.	0.8	25
43	Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome. Clinical Cancer Research, 2015, 21, 249-257.	3.2	497
44	The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations. Frontiers in Oncology, 2016, 6, 201.	1.3	82
45	Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival. International Journal of Cancer, 2016, 139, 1423-1430.	2.3	15
46	Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study. Abdominal Radiology, 2016, 41, 521-530.	1.0	12
47	PK–PD modeling of individual lesion FDG–PET response to predict overall survival in patients with sunitinib–treated gastrointestinal stromal tumor. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 173-181.	1.3	16
48	Novel drugs that target the metabolic reprogramming in renal cell cancer. Cancer & Metabolism, 2016, 4, 14.	2.4	64
49	Update on advances in molecular PET in urological oncology. Japanese Journal of Radiology, 2016, 34, 470-485.	1.0	31
50	Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. BMC Medicine, 2016, 14, 185.	2.3	29
51	Novel imaging in renal cell carcinoma. Current Opinion in Urology, 2016, 26, 388-395.	0.9	10
52	FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma. BMC Cancer, 2016, 16, 67.	1.1	54
53	The Role of PET Scanning in the Evaluation of Patients With Kidney Disease. Advances in Chronic Kidney Disease, 2017, 24, 154-161.	0.6	8
54	Metabolic reprogramming in clear cell renal cell carcinoma. Nature Reviews Nephrology, 2017, 13, 410-419.	4.1	323
55	Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. BMC Cancer, 2017, 17, 392.	1.1	14
56	One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival. Cancer Chemotherapy and Pharmacology, 2017, 79, 855-861.	1.1	16
57	Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine. Radiology, 2017, 284, 333-351.	3.6	46
58	The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy. BMC Cancer, 2017, 17, 39.	1.1	24

#	Article	IF	Citations
59	Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 199-205.	3.3	4
60	Renal Tumors. , 2017, , 1-58.		0
62	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	12.5	792
63	Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. International Journal of Molecular Sciences, 2017, 18, 1937.	1.8	15
64	Renal cell carcinoma: the search for a reliable biomarker. Translational Cancer Research, 2017, 6, 620-632.	0.4	78
65	Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges. Kidney Cancer, 2017, 1, 107-114.	0.2	8
66	FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 739-744.	1.1	15
67	Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case report. Gynecologic Oncology Reports, 2018, 24, 54-56.	0.3	1
68	Extraction of radiomic values from lung adenocarcinoma with near-pure subtypes in the International Association for the Study of Lung Cancer/the American Thoracic Society/the European Respiratory Society (IASLC/ATS/ERS) classification. Lung Cancer, 2018, 119, 56-63.	0.9	19
69	Imaging Advances in the Management of Kidney Cancer. Journal of Clinical Oncology, 2018, 36, 3582-3590.	0.8	16
70	Predictive value of positron emission tomography for the prognosis of molecularly targeted therapy in solid tumors. OncoTargets and Therapy, 2018, Volume 11, 8885-8899.	1.0	3
71	PET/CT Findings in Renal Cancer. , 2018, , 513-517.		0
72	Identification of a sodium pump Na + /K + ATPase Î±1-targeted peptide for PET imaging of breast cancer. Journal of Controlled Release, 2018, 281, 178-188.	4.8	23
73	Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma. Current Urology Reports, 2019, 20, 56.	1.0	16
74	Weight-loss with activation of brown fat: Suspect pheochromocytoma. Annales D'Endocrinologie, 2019, 80, 314-318.	0.6	3
75	24 Urological Tumors. , 2019, , .		0
76	Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. BMC Cancer, 2019, 19, 298.	1.1	24
77	Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and 99mTc-MDP Bone Scan in a Prospective Clinical Trial. Kidney Cancer, 2019, 3, 241-251.	0.2	2

#	Article	IF	Citations
78	Visual and semiquantitative analysis of 82Rb uptake in malignant tumors on PET/CT. Nuclear Medicine Communications, 2019, 40, 532-538.	0.5	5
79	FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma. Clinical and Experimental Medicine, 2019, 19, 143-148.	1.9	12
80	Herbicide biomonitoring in agricultural workers in Valle del Mayo, Sonora Mexico. Environmental Science and Pollution Research, 2020, 27, 28480-28489.	2.7	16
81	Biomarkers in renal cancer. , 2020, , 233-245.		0
82	Reprogramming of Metabolism in Kidney Cancer. Seminars in Nephrology, 2020, 40, 2-13.	0.6	22
83	Renal Mass Biopsy. , 2020, , .		1
85	Role of positron emission tomography/computed tomography in the evaluation of renal cell carcinoma. Indian Journal of Urology, 2021, 37, 125.	0.2	10
86	^{18}F-FDG positron emission tomography combined with computed tomography in renal cell carcinoma diagnostics. Onkourologiya, 2021, 16, 160-169.	0.1	0
87	[68Ga]Ga-PSMA-HBED-CC PET/CT demonstrates to be superior to ceCT in detecting early treatment response in metastatic clear cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3337-3339.	3.3	3
88	PET/CT Limitations and Pitfalls in Urogenital Cancers. Seminars in Nuclear Medicine, 2021, 51, 611-620.	2.5	7
89	Primary clear cell carcinoma of the rete testis: 1st report. BMJ Case Reports, 2015, 2015, bcr2014209000-bcr2014209000.	0.2	5
90	Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. Journal of Clinical Investigation, 2019, 129, 442-451.	3.9	76
91	Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma. PLoS ONE, 2016, 11, e0153321.	1.1	6
92	PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art. Indian Journal of Urology, 2018, 34, 20.	0.2	12
93	Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma. Nuclear Medicine Review, 2013, 16, 3-8.	0.3	31
94	EUS FNA of Altered Left Adrenal Gland Morphology Suggests Amending CT and PET-CT Attenuation Threshold Values That Predict Malignancy. Journal of Cancer Therapy, 2012, 03, 1029-1036.	0.1	0
95	Molecular Imaging for Renal Cell Carcinoma. , 2013, , 93-111.		0
96	Signaling Pathways and Biomarkers in Renal Tumors. , 0, , .		0

#	ARTICLE	IF	CITATIONS
98	Functional Imaging of Renal Cell Carcinoma. , 2014, , 1143-1171.		1
99	Nierenzellkarzinom. , 2014, , 347-397.		0
100	Development and Incorporation of Biomarkers in RCC Therapeutics. , 2015, , 527-539.		0
101	Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. , 2016, , 1-43.		0
102	Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. , 2017, , 839-881.		0
103	Chest Wall Metastasis from Renal Cell Carcinoma. , 2018, , 79-80.		0
104	Renal Mass Biopsy: Future Trends and Developments. , 2020, , 195-207.		0
105	Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with renal carcinoma. Medicine (United States), 2020, 99, e19988.	0.4	7
106	Urological Cancer. , 2021, , 77-93.		0
107	Molecular Imaging for Renal Cell Carcinoma. , 2020, , 99-118.		0
108	The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma. PLoS ONE, 2021, 16, e0259241.	1.1	22
109	Nierenzellkarzinom. , 2014, , 347-397.		0
110	New prognostic models in metastatic renal cancer. Translational Andrology and Urology, 2012, 1, 144-5.	0.6	0
111	PET imaging in renal and bladder cancers. , 2022, , .		0
113	Management of advanced genitourinary tumors. Tumori, 2012, 98, 264-6.	0.6	0
115	Molecular Imaging of Renal Cell Carcinoma in Precision Medicine. Molecular Pharmaceutics, 2022, 19, 3457-3470.	2.3	5
117	Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. , 2022, , 975-1022.		0
118	PET/CT in Renal Cancer. , 2022, , 87-92.		0

#	ARTICLE	IF	CITATIONS
119	[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma. Clinical Cancer Research, 2023, 29, 592-601.	3.2	7
120	Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters. Acta Radiologica, 2023, 64, 2040-2049.	0.5	2
121	Advances in Imaging-Based Biomarkers in Renal Cell Carcinoma: A Critical Analysis of the Current Literature. Cancers, 2023, 15, 354.	1.7	7
122	[18F]FDG PET/CT: Lung Nodule Evaluation in Patients Affected by Renal Cell Carcinoma. Tomography, 2023, 9, 387-397.	0.8	0
123	Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects. International Journal of Molecular Sciences, 2023, 24, 4615.	1.8	33